BOSTON, November 7, 2024 — For women diagnosed with early-stage, aggressive breast cancer, a new approach to treatment is showing significant promise. Adding immunotherapy to standard chemotherapy *before* surgery dramatically improves the chances of eliminating all traces of cancer, extending the time before the disease returns, and even increasing overall survival rates.
Immunotherapy Boosts Outcomes in Aggressive Breast Cancer
A new study reveals a powerful combination for women with early triple-negative breast cancer.
- Adding immunotherapy to chemotherapy before surgery significantly increases the likelihood of no detectable cancer at the time of operation.
- Patients receiving the combined therapy experience longer periods without cancer recurrence.
- Overall survival rates are improved with the addition of immunotherapy prior to surgery.
- Immunotherapy added *after* surgery does not appear to offer the same survival benefits.
Q: What does this mean for someone newly diagnosed with triple-negative breast cancer?
A: It suggests that incorporating immunotherapy into your treatment plan *before* surgery could substantially improve your prognosis, potentially leading to a longer, healthier life. However, it’s crucial to discuss the potential side effects with your oncologist.
Triple-negative breast cancer (TNBC), accounting for 12% to 17% of all breast cancer cases, is a particularly challenging form of the disease. Unlike other breast cancers, TNBC cells lack receptors for estrogen and progesterone, and don’t overexpress the HER2 protein, limiting treatment options. Chemotherapy remains the standard of care, but roughly 30% to 40% of patients with early TNBC will eventually see their cancer spread, even with this treatment.
Researchers have been exploring ways to enhance treatment effectiveness, and the latest findings point to the potential of combining chemotherapy with immunotherapy – a treatment that harnesses the body’s own immune system to fight cancer. Immunotherapy drugs, specifically PD-1 and PD-L1 inhibitors, work by removing the “brakes” on immune cells, allowing them to more effectively recognize and destroy cancer cells. Some cancer cells use signals involving the PD-1 and PD-L1 proteins to hide from the immune system; these inhibitors block that signal.
A comprehensive review of seven studies, encompassing 4,341 participants, revealed compelling results. Two studies utilized the PD-1 inhibitor pembrolizumab, while five employed PD-L1 inhibitors such as durvalumab and atezolizumab. The majority of the studies (six) administered treatment *before* surgery, with one evaluating the combination *after* surgery.
Patients who received the combination of immunotherapy and chemotherapy *before* surgery experienced a remarkable improvement in several key areas:
- Approximately twice as many patients showed no signs of cancer at the time of surgery.
- The length of time patients lived without cancer returning was significantly extended.
- Overall survival – the time from diagnosis or treatment initiation to death from any cause – was also improved.
Interestingly, the single study examining the combination *after* surgery did not demonstrate the same survival benefits. There was no apparent improvement in survival outcomes for patients receiving immunotherapy post-surgery.
Researchers acknowledge limitations in the evidence. While confident in the positive impact of pre-surgical immunotherapy, they express moderate to low confidence in the results of post-surgical treatment due to the small sample size of the single study and the possibility of patient awareness regarding their assigned treatment. Further research is needed to understand how PD-1 or PD-L1 inhibitors work in different patient subgroups and to assess the impact on quality of life during and after treatment.
The evidence reviewed is current as of November 6, 2024.
Frequently Asked Questions
- What is triple-negative breast cancer?
TNBC is an aggressive type of breast cancer that lacks common receptors, making it harder to treat with traditional hormone therapies. - What are PD-1 and PD-L1 inhibitors?
These drugs help the immune system recognize and attack cancer cells by blocking signals that cancer cells use to hide. - When is the best time to add immunotherapy to chemotherapy?
The research suggests that adding immunotherapy *before* surgery yields the most significant benefits for patients with early TNBC.
This research offers a hopeful step forward in the fight against aggressive breast cancer. As with any medical decision, patients should discuss these findings with their healthcare team to determine the best course of treatment for their individual circumstances.
